Trial Design

John R. Sims, senior vice president and head of global development, and Dawn A. Brooks, director of clinical development; both with Eli Lilly discuss the design of the TRAILBLAZER-ALZ program.

Research can reveal vital information about treatments in the long run.

Survey examines trial enrollment motivation among diverse populations.

Webinar Date/Time: Wednesday, March 29, 2023 at 11am ET |10 am CT | 8am PT

Webinar Date/Time: Thu, Mar 2, 2023 1:00 PM EST

Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT

Webinar Date/Time: Thursday, March 30th, 2023 at 10am EDT|7am PDT|3pm BST|4pm CEST

Laboratory services organization focuses on easing patient and site burden with improved collection device.

Webinar Date/Time: Thu, Mar 9, 2023 11:00 AM EST

Webinar Date/Time: Tue, Mar 14, 2023 11:00 AM EDT

Webinar Date/Time: Tuesday, February 14th, 2023 at 10am EST|7am PST|3pm GMT|4pm CET

Gillian Livock, SVP & general manager, customer engagement at Medable and Noolie Gregory, VP of DCT operations at Syneos Health discuss how combining technology with clinical operations delivers better data and clinical trial patient oversight.

Webinar Date/Time: Thu, Jan 26, 2023 11:00 AM EST

Despite agreement on recommendations between European regulators, DCT unclarity remains.

Webinar Date/Time: Tuesday, January 24th, 2023 at 11am EST|8am PST|4pm GMT|5pm CET

The Digital Medicine Society (DiMe) CEO Jennifer Goldsack and Takeda’s Head of Digital Health Sciences, Data Sciences Institute Shoibal Datta describe the current landscape of digitized clinical trials and the decisions needed to fully utilize their potential.

Webinar Date/Time: Wed, Nov 30, 2022 10:00 AM EST

Anticipating the need for both virtual and traditional sites during the planning process can provide high ROI for sponsors.

Webinar Date/Time: Wednesday, December 7th, 2022 at 11am EST | 8am PST | 4pm GMT | 5pm CET

What is next for DCTs after acceleration from COVID-19?

Sites not expected to fade away even as DCTs continue to grow past COVID-19.

Identifying and providing clarity on the GCP quality and risk concerns associated with DCT modalities.

Tufts CSDD study in collaboration with ten biopharmaceutical organizations and CROs examines sponsor/CRO relationships.

Ken Getz, executive director and research professor at the Tufts Center for the Study of Drug Development, discusses the value of breakthrough findings with ROI and eNPV models.

Richard Young previously explained on ACT why sponsors need a strong data foundation for successful digital clinical trials. Now he focuses on how to address some of the associated data management challenges.

DCTs can be a great tool for small-to-midsize pharma and biotech companies despite misconceptions of them being advantageous for only Big Pharma.

Patients reap benefits of strong collaboration in executing DCTs.

How DCTs can impact pharmaceutical companies exploring DTx combination products and standalone DTx studies.

As market factors drive the rapid growth of decentralized clinical trials, organizations should embrace risk-based quality management to evaluate the new dimensions of risk and ensure effective oversight of disparate data sources, writes John Hall.

Industry provides endless methods in crafting solutions for patients.